SAN RAFAEL, Calif.,
June 29, 2020 /PRNewswire/
-- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced
the promotions of Brian R. Mueller
to Executive Vice President, Chief Financial Officer and of
Andrea L. Acosta to Group Vice
President, Chief Accounting Officer. Mr. Mueller had been
serving as Senior Vice President, Acting CFO since February this
year.
"After an exhaustive search of internal and external candidates,
Brian was the most qualified as a 17-year veteran at BioMarin in
finance combined with his demonstration of leadership as acting
CFO. I am confident that Brian's experience, skills, and
commitment to the Company will be integral to our growth into
profitability," said Jean-Jacques Bienaimé, Chairman and Chief
Executive Officer at BioMarin. "It also was clear that
Andrea's leadership within our Finance organization and experience
made her the most qualified candidate for Chief Accounting Officer
to assume Brian's previous role. It is a credit to BioMarin
that we have such deep bench strength in our finance organization
to be able to promote two highly qualified people into these key
leadership roles as the company transitions into its next
evolutionary phase of growth."
"It is an honor to be selected for the CFO role at
BioMarin. I have been a part of the Company's growth over the
last two decades, and I am looking forward to continuing to support
our efforts to develop therapies that make a meaningful difference
in small patient populations," said Brian
R. Mueller, Executive Vice President, Chief Financial
Officer. "As the company continues to develop breakthrough
therapies for rare disease patients, the Finance function is
positioned as a strategic partner to our critical research and
development, technical, and commercial operations."
"I am looking forward to bringing my experience to the role of
Chief Accounting Officer and to supporting the Company's strategic
goals over the coming years," said Andrea
L. Acosta, Group Vice President, Chief Accounting
Officer. "It is important that the crucial work that BioMarin
is doing to advance the standard of care for rare disease patients
is supported by a finance organization that is sensitive to the
specific needs to fuel innovation."
Mr. Mueller has been with BioMarin since December 2002, during which time he has taken on
roles of increasing responsibility. Prior to being Senior
Vice President, Acting CFO, he served as Senior Vice President,
Finance and Chief Accounting Officer and as Group Vice President,
Corporate Controller. Before joining BioMarin, Mr. Mueller
worked for KPMG as a senior manager in the firm's audit practice.
Mr. Mueller joined KPMG after Arthur Andersen LLP ceased operations
in June 2002, prior to which he spent
seven years with Arthur Andersen LLP in the firm's audit and
business advisory services practice. From June 2014 to May
2020, Mr. Mueller was a member of the board of directors of
Anthera Pharmaceuticals, Inc., a previously public
biopharmaceutical company, where he also served as Chairman of the
Audit Committee. Mr. Mueller received a B.S. in Accountancy
from Northern Illinois University in
DeKalb, Illinois, and is a member
of the American Institute of Certified Public Accountants.
Ms. Acosta joined BioMarin in 2017 as Vice President, Corporate
Controller. Prior to BioMarin, Ms. Acosta worked at Levi
Strauss & Co. as Vice President, Global Controller and
Principal Accounting Officer where she had various roles of
increasing responsibility in finance management during her
tenure. Previously, she worked at KPMG LLP as a manager in
the firm's audit practice. She earned a BS in Accounting at
San Francisco State University and is a
Certified Public Accountant.
About BioMarin
BioMarin is a global biotechnology company that develops and
commercializes innovative therapies for patients with serious and
life-threatening rare and ultra-rare genetic diseases. The
company's portfolio consists of six commercialized products and
multiple clinical and pre-clinical product candidates. For
additional information, please visit www.biomarin.com.
Information on such website is not incorporated by reference into
this press release.
Forward-Looking Statement
This press release contains forward-looking statements about the
business prospects of BioMarin Pharmaceutical Inc. (BioMarin),
including, without limitation, statements about: Mr. Mueller's
promotion and his anticipated contributions to the company's growth
and profitability, Ms. Acosta's promotion, and the Company's
ability to execute on its growth and profitability goals. These
forward-looking statements are predictions and involve risks and
uncertainties such that actual results may differ materially from
these statements. These risks and uncertainties include, among
others: Mr. Mueller continuing employment as anticipated,
possible complications associated with the leadership transition
within the Finance organization, and those factors detailed in
BioMarin's filings with the Securities and Exchange Commission
(SEC), including, without limitation, the factors contained under
the caption "Risk Factors" in BioMarin's Quarterly Report on Form
10-Q for the quarter ended March 31,
2019 as such factors may be updated by any subsequent
reports. Stockholders are urged not to place undue reliance on
forward-looking statements, which speak only as of the date hereof.
BioMarin is under no obligation, and expressly disclaims any
obligation to update or alter any forward-looking statement,
whether as a result of new information, future events or
otherwise.
BioMarin® is a registered trademark of BioMarin Pharmaceutical
Inc.
Contact:
|
Investors:
|
Media:
|
Traci
McCarty
|
Debra
Charlesworth
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
(415)
455-7558
|
(415)
455-7451
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biomarin-promotes-company-veteran-brian-r-mueller-to-executive-vice-president-cfo-301085332.html
SOURCE BioMarin Pharmaceutical Inc.